Abstract:Background: The pluripotency factor known as Lin28 plays a crucial role in the regulation of cancer cell stem-like characteristics, hence facilitating the formation of cancer and the evolution of therapy-resistant tumors. The protein exerts its function by utilizing its cold shock domain and zinc knuckle domain (ZKD) to engage with the Let-7 pre-microRNA and impede the process of Let-7 production. The implementation of chemical agents to hinder the interaction between Lin28 and Let-7 has been proven as a therapeutic approach for treating aggressive tumors. Methods: Computer-aided drug design techniques were employed in the development of a novel series of small molecule inhibitors, which are derivatives of our previously identified lead compounds Ln115, Ln15, and Ln7. Fluorescent Polarization Assay (FP), and Electrophoretic Mobility Shift Assay (EMSA) were used to screen the chemicals as Lin28-Let7 interaction disruptors using Lin28A/B ZKD domain. To further screen the chemicals, the Incucyte cell proliferation assay was performed using two Lin28A and Lin28B positive cells, IGROV-1, and DuNE cells, respectively. The inhibition of Lin28 activity was subsequently evaluated by measuring Let-7 micro-RNA and Lin28 protein levels using RT-PCR and Western Blot. Then, the metabolism profile was explored using Microsomal Stability Assay. Incucyte proliferation assay and MTS assay determined the IC50 of lead compound in Lin28 positive cells. The anti-stemness properties of the lead compound were subsequently evaluated through assays for stem gene expression levels and colony formation. To evaluate the potential of the lead compound to further move into animal studies, we tested it on a newly developed 3D Neuroendocrine Prostate Cancer (NEPC) model. Results: In this study, we provide a novel set of derivatives, within which, Ln268 was chosen as the lead compound. Ln268 shows higher metabolic stability with a half-life time of 462 min and clearance rate of 5 ul/min/mg, compared to its father compound at 347 min and 46 ul/min/mg, respectively. Ln268 treatment resulted in a time-dependent inhibition of cell growth with an IC50 of 2.5 uM at 72 hrs. Ln268 reduces mRNA levels of stemness and neurodifferentiation markers such as CHGA, CHG, SYP, SCGN, OCT3/4, NANOG, ID4, FOXC1, ALDH1A2, and FOXO3. In the 3D NEPC model, Ln268 suppresses spheroid growth in a dose- and time-dependent manner. Ln268 achieved 100% spheroid growth inhibition at the concentration of 100 uM, while the current commercially available C1632 only reached 50%. Conclusion: We discovered a novel Ln15 derivative named Ln268, which has a better metabolism profile and increased inhibitory activity to distrust Lin28-Let7 interaction and cancer cell proliferation. Ln268 has the potential to be improved and used as an anti-cancer treatment for a variety of malignancies, such as prostate cancer. Citation Format: Victor M. Matias-Barrios, Mariia Radaeva, Graciella Rosellinny, Artem Cherkasov, Xuesen Dong. Optimization of Lin28 inhibitors: A promising therapeutic approach for the suppression of cancer cell proliferation, stemness properties, and spheroid growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1815.

Abstract 1818: Novel efficient isolation and water-soluble prodrug preparation of anti-cancer natural product narciclasine

Antineoplastic agents 500. Narcistatin

Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells

Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability via Structural Modification and Nanotechnology

Synthesis, Characterization, and Biological Evaluation of Novel Naringenin Derivatives as Anticancer Agents

Abstract 4479: Design, synthesis, and evaluation of amino acid conjugated niclosamide prodrugs as a PepT1 substrate

Improving Anticancer Therapy with Naringenin-Loaded Silk Fibroin Nanoparticles

Novel ST1926 Nanoparticle Drug Formulation Enhances Drug Therapeutic Efficiency in Colorectal Cancer Xenografted Mice

Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets

Abstract 4692: A novel ceramide synthase 2 agonist and its implication in triple-negative breast cancer therapy

A Simple and Efficient Path for the Synthesis Antineoplastic Agent (2R,3R,4S,5R)-5-(6-Amino-2-Chloropurin-9-yl)-4-Fluoro-2-(Hydroxymethyl) oxolan-3-ol (Clofarabine)

Identification of Narciclasine from Lycoris Radiata (l'her.) Herb. and Its Inhibitory Effect on LPS-induced Inflammatory Responses in Macrophages

Abstract 1815: Optimization of Lin28 inhibitors: A promising therapeutic approach for the suppression of cancer cell proliferation, stemness properties, and spheroid growth

Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach.

Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

Inhalable chitosan-coated nano-assemblies potentiate niclosamide for targeted abrogation of non-small-cell lung cancer through dual modulation of autophagy and apoptosis

Current Status and De Novo Synthesis of Anti-Tumor Alkaloids in Nicotiana